EUCTR2016-003949-28-IT进行中(未招募)1 期
Incobotulinumtoxin versus Onabotulinumtoxin in the treatment of patients with overactive bladder syndrome - Inco_Ona1
PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA0 个研究点目标入组 140 人开始时间: 2021年6月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-patients (males and females) with neurogenic urge urinary incontinence (UUI) (with urgency, increase in day- time and night- time urinary frequency) and with urodynamic diagnosis of DO;
- •-18- 80 years;
- •-women of childbearing age, who use a reliable method of contraception throughout the study period (a pregnancy test must be performed during enrolment in the study);
- •-spinal cord injury at or below T1, diagnosed at least 6 months before the screening in case of a vesico-sphincter dysfunction due to spinal cord injury;
- •-EDSS score = 6, in MS patients;
- •-patients refractory to anticholinergic therapy (= 1 anticholinergic agent)
- •-application of intermittent catheterizations to empty the bladder. In the case of spontaneous micturition, the patients should agree for the use of intermittent catheterizations, in case this will be necessary after treatment with the detrusor injection of botulinumtoxin A.
- •Urodynamic characteristics:
- •urodynamic diagnosis of DO, refractory to standard anticholinergics and naïve to intradetrusor injection of onabotulinumtoxin A.
- •The wash- out period after anticholinergics has to be of at least 3 weeks.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •-recurring urinary tract infections (UTIs) (= 4 episodes/year);
- •-spinal cord injuries above T1;
- •-MS patients: EDSS score = 6;
- •-patients who won’t or can’t perform intermittent catheterization;
- •-pregnancy or breast- feeding, if female patients
- •-post- void residual volume (PRV) > 150 ml, in the case of spontaneous micturition
研究者
相似试验
Unknown
3 期
Overactive Bladder Syndrome: Incobotulinumtoxin Versus OnabotulinumtoxinOveractive Bladder SyndromeNCT03758235University Of Perugia140
尚未招募
3 期
medical versus surgical treatment in idiopathic clubfoot patientsCTRI/2021/01/030466AIIMS RAIPUR
已完成
不适用
Effects of Botulinum Toxin Type A in patients with chronic orofacial paiTemporomandibular Joint Dysfunction SyndromeC05.500.607.221.897RBR-8fsspyyFaculdade de Odontologia de Bauru, Universidade de São Paulo
招募中
3 期
Efficacy of MASPORT in BlepharospasmBenign Essential Blepharospasm (BEB).BlepharospasmG24.5IRCT20240216061023N1Shahid Beheshti University of Medical Sciences19
已完成
不适用
Assessment of efficacy of Botulinium toxin A for treatment of keloidkeloid scar.Hypertrophic scarIRCT2014071918533N1euronox company(Tehran reseller)20
